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Abstract
Background: The prevention of malaria faces with the repeated emergence of Plasmodium falciparum resistance to
drugs, often involving point mutations of the target gene. In the pregnant woman, currently the WHO
recommendation is the administration of an intermittent preventive treatment (IPTp) with sulphadoxine-
pyrimethamine. Sulphadoxine-pyrimethamine (SP) resistance has increased for several years in Africa, stressing the need
for alternative molecules. In this context, the first randomized clinical trial comparing the efficacy of SP and mefloquine
for IPTp has been conducted recently in Benin. Using samples from this trial, the current study evaluated and quantified
the prevalence of mutations on the pfdhfr and pfdhps genes as well as the copy number of the pfmdr1 gene in
parasites from P. falciparum-infected pregnant women before first and second IPTp administration, and at delivery.
Methods: PCR-restriction fragment length polymorphism of polymorphic codons of the pfdhfr gene (51, 59, 108, and
164) was performed. The identification of mutations in three codons of the pfdhps gene (436, 437 and 540) was
achieved by PCR and sequencing. Copy number quantification for pfmdr1 gene was performed using real-time PCR.
Results: Results show a high prevalence rate of mutant parasites in women taking IPTp with sulphadoxine-
pyrimethamine or mefloquine. The prevalence of triple and quadruple mutants was high before first drug regimen
administration (79/93, 85%), and remained similar until delivery. Infection with mutant parasites was not correlated
with low birth weight nor placental infection. In all samples, the copy number of pfmdr1 gene was equal to one.
Conclusions: The clinical trial comparing SP and mefloquine efficacy during IPTp showed SP remained efficacious in
preventing low birth weight. The present study shows a high prevalence of triple and quadruple mutations implicated
in SP resistance. Although the pfdhfr/pfdhps triple and quadruple mutations were frequent, there was no evidence of
correlation between these genotypes and the lack of efficacy of SP in the context of IPTp. Nevertheless, it is now
obvious that SP will soon be compromised in whole Africa. Molecular markers have been recommended to monitor SP
efficacy for IPTp, but given the current prevalence of mutant parasites their usefulness is questionable.
Background
Plasmodium falciparum infection during pregnancy is
responsible for placental infection, and constitutes a
substantial risk for the mother, her foetus, and the neo-
nate. It is a major cause of anaemia and maternal death,
and one of the main causes of low birth weight (LBW).
The WHO recommends protecting the women during
pregnancy using intermittent preventive treatment
(IPTp) with one curative regimen of sulphadoxine-pyri-
methamine (SP) (1,500 mg sulphadoxine and 75 mg pyr-
imethamine), at least twice during pregnancy, once
during the 2
nd trimester, and then at least one month
apart. IPTp with SP has proven efficacious in reducing
the burden of pregnancy-associated malaria (PAM), and
is currently part of the national malaria prevention pro-
gramme in most African countries.
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in Benin, showing that SP-IPTp is effective both in
reducing the LBW rate, as compared to chloroquine
prophylaxis (10% with SP-IPTp given as national policy
and 8.7% in a controlled IPTp trial ([1], vs. 15.7% with
chloroquine [2]), and the malaria placental infection
prevalence rate (11.2% vs. 2.9% and 16.7%, respectively),
with a good overall compliance of the national IPTp [3].
However, resistance to SP is developing increasingly in
Africa. Several molecular epidemiology studies showed
that resistance to pyrimethamine is associated with the
acquisition of mutations in the gene coding for dihydro-
folate reductase (pfdhfr) (S108N, N51I, and C59R, and
I164L) [4,5]. The S108N mutant exhibits a low level of
resistance, the N51I/S108N or the C59R/S108N double
mutants intermediate levels of resistance, and the N51I/
C59R/S108N triple mutant has a higher level of resis-
tance to pyrimethamine. Similarly, resistance to sulpha-
doxine is due to three mutations in the gene encoding
dihydropteroate synthase (pfdhps) (S436F, A437G,
K540E) [6,7]. Each successive mutation causes a greater
decrease in sensitivity respectively to pyrimethamine
and sulphadoxine. It has been showed that the increased
prevalence of mutations on the pfdhfr and pfdhps gene
is linked to intensive use of SP. Indeed, a study showed
that the frequency of the triple pfdhfr (N51I, C59R,
S108N) and double pfdhps (A437G, K540E) mutants
increased by 37% - 63% and 200% -300% respectively
when SP was used as the first line treatment of malaria
attacks [8]. Another study showed that the frequency of
pfdhfr mutations increased, especially after the change
in treatment policy [9].
In many countries, SP now demonstrates inadequate
therapeutic efficacy in children under 5 years old, and is
no longer the drug of choice for treatment. However,
data collected in young children cannot be extrapolated
to pregnant women, in whom SP IPTp seems to still
retain its efficacy [10,11]. Nevertheless, the reducing
activity of SP requires further investigations, especially
in the context of IPTp. To date, mefloquine (MQ) is
one of the most attractive alternatives to SP for IPTp. A
randomized trial comparing the efficacy of SP and MQ
for IPTp has recently been completed in Benin [11],
s h o w i n gt h a tS PI P T pk e p te f f i c a c yi nac o n t e x to f
growing resistance to SP [12]. Indeed, SP and MQ were
found to be equivalent and highly efficacious in the pre-
vention of LBW.
This study was extended with the aim to search for
mutations of the genes associated to SP resistance and
to evaluate the copy number of pfmdr1 gene during
pregnancy and at delivery in Beninese women under
IPTp. This exploratory investigation looked at the
impact of the point mutations on the outcome of
pregnancy.
Methods
Study site and subjects
A randomized clinical trial comparing the efficacy of SP
and MQ for IPTp was conducted from July 2005 to
April 2008 in the rural city of Ouidah, Benin. A total
1,601 women were randomized to receive MQ (n = 802)
or SP (n = 799). All enrolled women were followed
from their first antenatal care visit at the 2
nd trimester
of pregnancy until delivery. The treatment consisted of
two curative doses of SP (1,500 mg of sulphadoxine and
75 mg of pyrimethamine per dose) or MQ (15 mg/kg
per dose). Drugs were administered under observation.
At the time of IPTp administration (first and second
doses given during the 2
nd and 3
rd trimesters of preg-
nancy), and at delivery, blood was collected for thick
smear confection and filter paper blotting. Details of
this clinical trial have been previously reported [11].
All filter papers corresponding to positive blood
smears were analysed for pfdhfr and pfdhps mutations
and pfmdr1copy number. At delivery, samples from all
women presenting or having presented with at least one
positive smear during the follow-up were analysed, even
if concomitant thick blood smear was negative.
DNA extraction and genotyping of point mutations
Blood collected on filter paper spots was dried and con-
served at room temperature until DNA extraction using
“Qiagen Kit” [13]. Genotyping for mutations in codons
51, 59, 108, and 164 of the pfdhfr gene was achieved by
a technique of DNA amplification by PCR of 40 cycles
with 4 μl DNA extract [14,15]. The amplicon obtained
was 718 bp and was submitted to a second PCR of 25
cycles with 1 μl of the first PCR product to frame areas
of interest. The fragment size obtained varied between
189 and 412 bp. The PCR products were digested by
restriction enzymes that varied with the studied codon
(Tsp509I, XMN I, Alu I, and Dra I, respectively). For
c o d o n5 1 ,t h ep r e s e n c eo ft w oD N Ab a n d so f1 4 8b p
and 64 bp demonstrates a wild genotype, and contrasts
to a single band of 212 bp observed with a mutant gen-
otype. Similarly, for codons 108 and 164, a wild geno-
type is characterized by two or three bands of 322 to 54
bp and 171, 135, 106 bp, respectively. The mutant geno-
type exhibits a single band of 376 pb for codon 108, and
four bands of 143, 135, 106 and 28 pb for codon 164.
Finally at codon 59, a mutant genotype is characterized
by two bands of 162 and 27 pb, and a wild genotype by
a single band of 189 pb. For each analysis, control
strains were used, consisting in both the 3D7 strain
(wild type for pfdhfr)a n dt h eW 2a n dV / 1 Ss t r a i n s
(mutant type for pfdhfr) [16-18].
Genotyping for mutations of the pfdhps gene in
codons 437, and 540 was performed by PCR of 35 cycles
with 2 μl of DNA extract [15,19,14]. The PCR product
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these 2 codons was achieved by sequencing (ABI prism
310). The copy number for pfmdr1 gene was quantified
by real-time PCR according to Sidhu et al and Price
et al [20,21].
Statistical analysis
Data analysis was performed using STATA
® 9.0 (Stata
Corporation, College Station, Texas, USA). Differences
between proportions were compared using the Pearson
chi-square or Fisher’s exact test. Continuous variables
were compared using the Wilcoxon test. The level of
statistical significance retained was p < 0.05. Nine
women were infected twice during pregnancy. Because
of non-independent data, they were excluded from the
analysis comparing the proportions of mutant parasites
at different time-points during pregnancy.
Results and discussion
A total of 181 women were infected during pregnancy,
and among them nine were infected twice. They pre-
sented an average age of 23 years, and 41% were primi-
gravidae. A total of 110 women had received SP, and 71
had received MQ. From the 190 samples collected and
analysed, 160 genotyping were successful. A total of 113
samples collected at inclusion (before first IPTp dose),
31 at second IPTp administration (two months later in
average), and 46 at delivery were investigated (Figure 1).
A single copy of the pfmdr1 gene was found in parasites
from all pregnant women at first and second IPTp
administrations, as well as at delivery. This result indi-
cates that the parasites present in these women were all
of wild-type genotype for the pfmdr1gene.
At inclusion, the prevalence of triple pfdhfr mutant
was 85% in parasites sampled from the 96 women,
before any drug administration. Similar prevalence rates
w e r eo b s e r v e di nt h eM Qa n dS Pg r o u p s( T a b l e1 ) .
Mutation at codons pfdhfr 164 and pfdhps 540 was not
observed in any sample, thus no quintuple mutants
were observed. The proportion of pfdhfr triple mutant
parasites (51, 59, and 108) did not vary significantly at
the 3 sampling times, neither in the SP group (80% vs.
92% vs. 68%; P = 0.33) nor in the MQ group (90% vs.
89% vs. 64%; P = 0.07) (Table 1). Similarly, the preva-
lence of quadruple mutations (at codons 51, 59, and 108
of the pfdhfr gene and codon 437 of the pfdhps gene)
did not vary at the 3 sampling times (74% vs. 92% vs.
61%; P = 0.19 for the SP group, and 81% vs. 71% vs.
60%; P = 0.39 for the MQ group). Women having pre-
sented more than one infection during follow-up, and
thus being included in more than one group, were
excluded from those analyses to avoid data dependency.
At delivery, the prevalence of triple or quadruple
mutant parasites did not differ between the MQ and SP
groups (64% vs 70%; P = 0.48; and 60% vs 65%; P =
0.54, respectively) (Table 1).
Such a high prevalence of mutations at inclusion,
before any drug administration, is not surprising as pre-
valence rates above 50% of the triple pfdhfr mutant were
also reported in Viet Nam [22], Malaysia [23], and Brazil
[24]. In Africa, this rate ranges from 40% [25,26] to 75%
[27,28]. These results in the context of IPTp are also
similar to those published by Bouyou-Akotet et al [29],
where the prevalence rates of triple and quadruple
mutants were 80% and 53%, respectively. Such a high
prevalence rate of mutations at inclusion heavily impairs
any conclusion on the possible selection of parasite
populations inducing an increase in resistance to SP. A
very high number of infected pregnant women would be
required for such an investigation. Even in areas of
intense P. falciparum transmission, the expected propor-
tion of women infected at enrolment may be relatively
high (in the 15 to 25% range), but is drastically reduced
(to a few percents) in women receiving IPTp. This study
included 1601 pregnant women, a significant number of
women. However, given the high prevalence of mutants
at inclusion, the power to detect a limited increase of
£ women with positive thick blood smear and/or positive Plasmodium falciparum PCR
* 2 women infected at the first and second IPTp administrations
** 3 women infected at the first IPTp administration and at delivery; 4 women infected at 
the second IPTp administration and at delivery  
1 601 randomised
(802 MQ-IPTp and 799 SP-IPTp)
1 601 given first IPTp dose
- 113 infected 
£
- 96 successfully genotyped
- 82 infected with mutant parasites 
1 470 given second IPTp dose
- 31 infected 
£*
- 26 successfully genotyped 
- 23 infected with mutant parasites 
1 346 women at delivery
- 46 infected 
£**
- 38 successfully genotyped 
- 26 infected with mutant parasites 
Figure 1 Study profile. IPTp, intermittent preventive treatment
during pregnancy; SP, sulphadoxine-pyrimethamine; MQ,
mefloquine.
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There was no difference in parasitaemia between women
infected with mutant parasites compared to women with
wild parasites neither at inclusion (median parasitaemia:
1408/mm3 vs. 1236/mm3, P = 0.89) nor at delivery in
the SP group (median parasitaemia: 7714/mm3 vs. 15
743/mm3, P = 0.86). In addition, the genotyping results
were not correlated with clinical efficacy of the drug, as
assessed by placental infection or low birth weight (birth
weight < 2,500 g) rates. The risk of placental infection
did not differ in the absence or in the presence of triple
and/or quadruple mutants during pregnancy in the SP
group (0% (0/10) vs 2.4% (1/41); P = 0.81). Similarly, the
risk of low birth weight baby did not differ in the
absence or in the presence of triple or quadruple
mutants during pregnancy. The mean weight of off-
spring of women infected during pregnancy (at inclusion
or at second administration of IPTp) was 2724 g (2473-
2975) if a triple or quadruple mutant was present, and
2808 g (2672-2944) if not (P = 0.29).
The women who were infected at delivery were often
n o tt h es a m ea st h o s ep r e v i o u s l yi n f e c t e db yat r i p l eo r
quadruple mutant parasite. In other words, women
infected by a triple or quadruple mutant parasite during
their pregnancy showed no increased risk for placental
infection, as compared to women infected with wild
type parasites. This suggests a lack of correlation
between multiple pfdhfr/pfdhps mutations and SP failure
in the context of IPTp, as assessed by the presence of a
placental infection.
Conclusion
The very high proportion of pfdhfr/pfdhps triple and
quadruple mutations observed in this study (64 to 89% of
infections for the three-time monitoring) did not allow to
conclude statistically, although it is unlikely that infection
with these genotypes actually correlates to the lack of
efficacy of SP in the context of IPTp. Indeed, the current
study shows that SP retained efficacy in preventing pla-
cental infection. Nevertheless, it is now obvious that SP
will soon be compromised in whole Africa, and an urgent
need exists to assess alternative drug regimens for IPTp,
as well as to monitor SP efficacy for IPTp by other means
than molecular markers [30]. Molecular markers have
been recommended, but given the current prevalence of
mutant parasites, their usefulness is questionable, and
alternative strategies have to be developed.
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